Antipsychotics

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

Research from Australia shows that "remained pervasive" in 70% of a sample of 83 patients medicated with antipsychotics and other medications, and concludes that...

A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.